Expression of microphthalmia transcription factor, S100 protein, and HMB-45 in malignant melanoma and pigmented nevi

Xia,Jianxin; Wang,Yanlong; Li,Fuqiu; Wang,Jinfeng; Mu,Yan; Mei,Xianglin; Li,Xue; Zhu,Wenjing; Jin,Xianhua; Yu,Kai

doi:10.3892/br.2016.732

Expression of microphthalmia transcription factor, S100 protein, and HMB-45 in malignant melanoma and pigmented nevi

Authors:
- Jianxin Xia
- Yanlong Wang
- Fuqiu Li
- Jinfeng Wang
- Yan Mu
- Xianglin Mei
- Xue Li
- Wenjing Zhu
- Xianhua Jin
- Kai Yu
View Affiliations

Affiliations: Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China
Published online on: August 1, 2016 https://doi.org/10.3892/br.2016.732
Pages: 327-331
Copyright: © Xia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma (MM) is a type of malignant tumor, which originates from neural crest melanocytes. MM progresses rapidly and results in a high mortality rate. The present study aims to investigate the expression of microphthalmia transcription factor (MITF), the S100 protein, and HMB-45 in MM and pigmented nevi. A total of 32 MM samples (including three skin metastasis, three lymph node metastasis and two spindle cell MM samples), two Spitz nevus samples, four pigmented nevus samples and two blue nevus samples were collected. The expression levels of S100 protein, HMB-45, and MITF were observed via immunostaining. The S100 protein exhibited high positive rates in MM and pigment disorders (96.7 and 100%, respectively), but with low specificity. The S100 protein was also expressed in fibroblasts, myoepithelial cells, histocytes and Langerhans cells in normal skin samples. HMB-45 had high specificity. Its positive expression was only confined to MM cells and junctional nevus cells. Furthermore, HMB-45 was not expressed in melanocytes in the normal tissue samples around the tumor or in the benign intradermal nevus cells. MITF exhibited high specificity and high sensitivity. It was expressed in the nuclei of melanocytes, MM cells and nevus cells. It was observed to be strongly expressed in metastatic MM and spindle cell MMs. Thus, MITF may present as a specific immunomarker for the diagnosis and differential diagnosis of MM.

View Figures

View References

1	Rastrelli M, Tropea S, Rossi CR and Alaibac M: Melanoma: Epidemiology, risk factors, pathogenesis, diagnosis and classification. Vivo. 28:1005–1011. 2014.
2	National Collaborating Centre for Cancer. Melanoma: Assessment and management. National Institute for Health and Care Excellence; London: 2015
3	Tripp MK, Watson M, Balk SJ, Swetter SM and Gershenwald JE: State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. May 27–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
4	Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L, Hemmi S and Dummer R: In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68:650–656. 2008. View Article : Google Scholar : PubMed/NCBI
5	Scolyer RA, Li LX, McCarthy SW, Shaw HM, Stretch JR, Sharma R and Thompson JF: Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens. Melanoma Res. 14:263–268. 2004. View Article : Google Scholar : PubMed/NCBI
6	Fleming JM, Ginsburg E, Oliver SD, Goldsmith P and Vonderhaar BK: Hornerin, an S100 family protein, is functional in breast cells and aberrantly expressed in breast cancer. BMC Cancer. 12:2662012. View Article : Google Scholar : PubMed/NCBI
7	Nipp M, Elsner M, Balluff B, Meding S, Sarioglu H, Ueffing M, Rauser S, Unger K, Höfler H, Walch A, et al: S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging. J Mol Med (Berl). 90:163–174. 2012. View Article : Google Scholar : PubMed/NCBI
8	Hilly O, Koren R, Raz R, RathWolfson L, Mizrachi A, Hamzany Y, Bachar G and Shpitzer T: The role of s100-positive dendritic cells in the prognosis of papillary thyroid carcinoma. Am J Clin Pathol. 139:87–92. 2013. View Article : Google Scholar : PubMed/NCBI
9	Bishop PW, Menasce LP, Yates AJ, Win NA and Banerjee SS: An immunophenotypic survey of malignant melanomas. Histopathology. 23:159–166. 1993. View Article : Google Scholar : PubMed/NCBI
10	Gao Z, Stanek A and Chen S: A metastatic melanoma with an unusual immunophenotypic profile. Am J Dermatopathol. 29:169–171. 2007. View Article : Google Scholar : PubMed/NCBI
11	Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, Testori A, Larue L and Goding CR: Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20:3426–3439. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lekmine F, Chang CK, Sethakorn N, Das Gupta TK and Salti GI: Role of microphthalmia transcription factor (Mitf) in melanoma differentiation. Biochem Biophys Res Commun. 354:830–835. 2007. View Article : Google Scholar : PubMed/NCBI
13	Granter SR, Weilbaecher KN, Quigley C and Fisher DE: Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol. 10:47–51. 2002. View Article : Google Scholar : PubMed/NCBI
14	Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J and Sarlomo-Rikala M: Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 25:205–211. 2001. View Article : Google Scholar : PubMed/NCBI
15	Hague A, Moorghen M, Hicks D, Chapman M and Paraskeva C: BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene. 9:3367–3370. 1994.PubMed/NCBI
16	Barnhill RL and Mihm MC Jr: The histopathology of cutaneous malignant melanoma. Semin Diagn Pathol. 10:47–75. 1993.PubMed/NCBI
17	Cochran AJ, Holland GN, Wen DR, Herschman HR, Lee WR, Foos RY and Straatsma BR: Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas. Invest Ophthalmol Vis Sci. 24:1153–1155. 1983.PubMed/NCBI
18	Gown AM, Vogel AM, Hoak D, Gough F and McNutt MA: Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 123:195–203. 1986.PubMed/NCBI
19	Denat L and Larue L: Malignant melanoma and the role of the paradoxal protein Microphthalmia transcription factor. Bull Cancer. 94:81–92. 2007.(In French). PubMed/NCBI
20	Koludrovic D and Davidson I: MITF, the Janus transcription factor of melanoma. Future Oncol. 9:235–244. 2013. View Article : Google Scholar : PubMed/NCBI
21	Nonaka D, Laser J, Tucker R and Melamed J: Immunohistochemical evaluation of necrotic malignant melanomas. Am J Clin Pathol. 127:787–791. 2007. View Article : Google Scholar : PubMed/NCBI
22	Ugurel S, Houben R, Schrama D, Voigt H, Zapatka M, Schadendorf D, Bröcker EB and Becker JC: Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res. 13:6344–6350. 2007. View Article : Google Scholar : PubMed/NCBI
23	King R, Googe PB, Weilbaecher KN, Mihm MC Jr and Fisher DE: Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol. 25:51–57. 2001. View Article : Google Scholar : PubMed/NCBI
24	Nybakken GE, Sargen M, Abraham R, Zhang PJ, Ming M and Xu X: MITF accurately highlights epidermal melanocytes in atypical intraepidermal melanocytic proliferations. Am J Dermatopathol. 35:25–29. 2013. View Article : Google Scholar : PubMed/NCBI